Clin2
NCT05740722Possibly a fitRecruiting

Nicotinamide riboside for progressive multiple sclerosis

Multiple SclerosisProgressive Multiple Sclerosis

Part of Brain & nervous system, Immune system & allergy clinical trials.

This Phase 2 trial studies whether a vitamin-like supplement called nicotinamide riboside can slow or improve disability in progressive multiple sclerosis. It may help people whose symptoms have been steadily getting worse over the last 2 years.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
300 people
Ages
18 years to 65 years
Study type
Interventional

Who can take part

  • You have a type of multiple sclerosis that is progressive (PPMS or SPMS), not relapsing MS
  • You are between 18 and 65 years old
  • Your nerve-function disability score (EDSS) is between 3 and 6.5
  • You can do a 25-foot walking test (T25FW)
  • Your MS disability has shown documented worsening within the last 24 months
  • You can consent and you may be on a stable MS medicine (or none) for the past 3 months

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06208527Recruiting· Phase 2
Nicotinamide Riboside for Frailty in Older Adults

This trial tests whether a daily supplement called nicotinamide riboside can help older adults who feel weak or frail to get stronger and more energetic. It lasts for several months and involves simple tests like a walking test and memory checks.

Bergen, Vestland
NCT05095571Recruiting
Extension study of vitamin supplements for ALS

This study looks at continuing a nicotinamide/pterostilbene supplement in people with ALS who already finished an earlier related NO-ALS study. It may help researchers learn whether the supplement can be continued safely and potentially benefit longer-term outcomes.

Bergen
NCT07741071Recruiting· Phase 2
Vitamin B3 supplement for early Alzheimer's disease

This study tests whether a daily supplement (nicotinamide riboside, a form of vitamin B3) can slow the progression of early Alzheimer's disease over two years. It is a randomized, double-blind trial, meaning half the participants will get the supplement and half will get a placebo (a pill with no active ingredient), and neither you nor the doctors will know which you are getting.

Bergen
NCT06162013Recruiting· Phase 2
NAD supplement trial for atypical parkinsonism

This trial tests whether a supplement called nicotinamide riboside (NR) can help people with rare forms of parkinsonism (PSP, MSA, or CBS). It is a double-blind study, meaning neither you nor the doctors will know if you are getting the real supplement or a placebo.

Oslo, Oslo
NCT06280482Recruiting· Phase 1
Nicotinamide Riboside for Moyamoya in Smooth Muscle Dysfunction

This trial tests a vitamin B3 supplement called nicotinamide riboside (NR) to see if it can help people with Smooth Muscle Dysfunction Syndrome (SMDS) who have a specific gene mutation. The goal is to improve blood flow problems in the brain (moyamoya-like disease) caused by the condition.

Houston, Texas
NCT06853743Recruiting· Phase 2
Study of nicotinamide riboside for Huntington's disease

This trial tests if a vitamin B3-like supplement, nicotinamide riboside, can help people with early to mid-stage Huntington's disease. You will be randomly assigned to take the supplement or a placebo to see if it slows the disease.

Oslo

Hear when a new Multiple sclerosis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.